» Articles » PMID: 34376719

Long Term Prognosis in Patients with Pulmonary Hypertension Undergoing Catheter Ablation for Supraventricular Tachycardia

Abstract

Various forms of supraventricular tachycardia (SVT) occur in patients with severe pulmonary hypertension (PH). Despite the high efficacy of radiofrequency catheter ablation (RFCA) for SVT, insufficient data exist regarding patients with PH. Thirty SVTs in 23 PH patients (age 47 [35-60] years; mean pulmonary artery pressure 44 [32-50] mmHg) were analyzed. Procedural success rate, short- and long-term clinical outcomes, were evaluated during a median follow-up of 5.1 years. Single-procedure success rate was 83%; 94% (17/18) in typical atrial flutter, 73% (8/11) in atrial tachycardia (AT), and 100% (1/1) in atrioventricular nodal reentrant tachycardia. Antiarrhythmic drugs, serum brain natriuretic peptide levels and number of hospitalizations significantly decreased after RFCA than that before (p = 0.002, 0.04, and 0.002, respectively). Four patients had several procedures. After last RFCA, 12 patients had SVT and 8 patients died. Kaplan-Meier curves showed that patients with SVT after the last RFCA had a lower survival rate compared to those without (p = 0.0297). Multivariate analysis identified any SVT after the last RFCA as significant risk factor of mortality (hazard ratio: 9.31; p = 0.016). RFCA for SVT in patients with PH is feasible and effective in the short-term, but SVT is common during long-term follow-up and associated with lower survival.

Citing Articles

Arrhythmias in Patients with Pulmonary Hypertension and Right Ventricular Failure: Importance of Rhythm Control Strategies.

Anand S, Cronin E J Clin Med. 2024; 13(7).

PMID: 38610631 PMC: 11012772. DOI: 10.3390/jcm13071866.


Radiofrequency catheter ablation for pulmonary hypertension patients with atrial flutter.

Zhang A, Ding L, Zhang H, Mi L, Yu F, Tang M ESC Heart Fail. 2024; 11(2):883-892.

PMID: 38200382 PMC: 10966254. DOI: 10.1002/ehf2.14659.


2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Joglar J, Chung M, Armbruster A, Benjamin E, Chyou J, Cronin E J Am Coll Cardiol. 2023; 83(1):109-279.

PMID: 38043043 PMC: 11104284. DOI: 10.1016/j.jacc.2023.08.017.


2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Joglar J, Chung M, Armbruster A, Benjamin E, Chyou J, Cronin E Circulation. 2023; 149(1):e1-e156.

PMID: 38033089 PMC: 11095842. DOI: 10.1161/CIR.0000000000001193.


Outcomes After Supraventricular Tachycardia Ablation in Patients With Group 1 Pulmonary Hypertension.

Satish T, Chin K, Patel N Cardiol Res. 2023; 14(5):403-408.

PMID: 37936620 PMC: 10627367. DOI: 10.14740/cr1556.


References
1.
Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View

2.
Soon E, Toshner M, Mela M, Grace A, Sheares K, Morrell N . Risk of potentially life-threatening thyroid dysfunction due to amiodarone in idiopathic pulmonary arterial hypertension patients. J Am Coll Cardiol. 2011; 57(8):997-8. DOI: 10.1016/j.jacc.2010.09.059. View

3.
Humbert M, Sitbon O, Simonneau G . Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351(14):1425-36. DOI: 10.1056/NEJMra040291. View

4.
McGlothlin D, Ivascu N, Heerdt P . Anesthesia and pulmonary hypertension. Prog Cardiovasc Dis. 2012; 55(2):199-217. DOI: 10.1016/j.pcad.2012.08.002. View

5.
Hoeper M, Lee S, Voswinckel R, Palazzini M, Jais X, Marinelli A . Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006; 48(12):2546-52. DOI: 10.1016/j.jacc.2006.07.061. View